However, many other drugmakers could capitalize on the soaring demand for weight loss medicines
Ideal for GLP1 users needing nourishment without heaviness
Employer Strategies SmithRx Key Takeaways GLP-1 demand has exploded for diabetes/weight loss, creating shortages and huge pharmacy spending that can force employers to raise premiums or cut coverage
Australia GLP-1 Receptor Agonist Market Companies AstraZeneca PLC Biocon Eli Lilly and Co Novo Nordisk A/S ADR Sanofi SA Latest Industry Leaders' Announcements On 21 May 2024, a complete ban on compounded tirzepatide and other compounded diabetes and weight loss medications was announced by the Australian government due to rising safety concerns and increased reports of patients experiencing side effects of these compounded drugs
[DOI] [PubMed] [Google Scholar] 5.Hiramoto B., McCarty T.R., Lodhia N.A., Jenkins A., Elnaiem A., Muftah M., Flanagan R., Chan W.W